Streetbeat News

Price Targets

PEN

Penumbra (NYSE:PEN) received mixed analyst ratings over the last three months, with 6 analysts offering diverse perspectives. The average 12-month price target is $269.00, with a high of $295.00 and a low of $240.00. Recent actions include both raised and lowered price targets and ratings. Penumbra develops medical devices and has shown a revenue growth of 26.8% as of September 30, 2023. However, it has below-average net margin, ROE, and ROA, but a low debt-to-equity ratio of 0.21. The company's market capitalization is below industry averages.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:01 pm

ALB

Analysts have provided mixed reviews on Albemarle (NYSE:ALB) over the past three months, with recent sentiment shifting negatively. The average 12-month price target has been reduced by 19.97% to $171.67. Analysts from firms including UBS, Deutsche Bank, Keybanc, B of A Securities, Piper Sandler, BMO Capital, RBC Capital, and Oppenheimer have adjusted their ratings and price targets, mostly lowering them. Albemarle is a major lithium producer with strong market presence, revenue growth, net margin, ROE, and ROA, and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:01 pm

GLW

Seven analysts have recently provided their ratings on Corning (NYSE:GLW), with a mix of opinions. The average 12-month price target is $32.43, down 10.64% from the previous $36.29. Analysts from UBS, JP Morgan, Citigroup, Barclays, Oppenheimer, Morgan Stanley, and Deutsche Bank have adjusted their price targets and ratings, reflecting a cautious outlook. Corning's financial health shows a strong market position with a high market cap and net margin, but revenue decline and high debt-to-equity ratio present challenges.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:00 pm

ACRS

Aclaris Therapeutics (NASDAQ:ACRS) has received mixed ratings from 4 analysts in the last three months, with 2 bullish and 2 indifferent ratings. The average 12-month price target is now $5.25, a significant drop from the previous $21.67. Analysts from HC Wainwright & Co. and Stifel have maintained and lowered their price targets, respectively, reflecting changes in market dynamics and company performance. Aclaris is a clinical-stage biopharmaceutical company with a focus on immuno-inflammatory diseases. Financially, the company has seen a -51.19% decline in revenue growth and has a net margin of -315.24%, with an ROE of -17.41% and an ROA of -12.89%. The company has no debt with a debt-to-equity ratio of 0.0.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:00 pm

GMED

Six analysts have recently updated their ratings on Globus Medical (NYSE:GMED), with a mix of bullish, somewhat bullish, and indifferent stances. The average 12-month price target is now $63.33, up from $59.50, with individual targets ranging from $53.00 to $75.00. Analyst actions include maintaining, raising, and lowering ratings and price targets. Globus Medical, a medical device company, has shown a significant revenue growth rate of 50.95% as of September 30, 2023, but has below-average net margin and ROE/ROA compared to the industry. The company's debt-to-equity ratio is healthy at 0.12.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

CTVA

Analysts have recently adjusted their ratings and price targets for Corteva (NYSE:CTVA), showing a negative shift in sentiment. The average 12-month price target is now $59.92, down 13.37% from previous estimates. Multiple analysts from firms such as UBS, Berenberg, and Morgan Stanley have lowered their price targets, reflecting changes in market conditions and company performance. Corteva's financial indicators show a decline in revenue growth, below-average net margin and ROE, and a conservative debt management approach. The company, a leader in seed and crop chemicals, was spun off from DowDuPont in 2019.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

MUR

Analysts have updated their ratings and price targets for Murphy Oil (NYSE:MUR), with 4 analysts offering diverse views. The average 12-month price target is now $52.00, up from $51.67. Tim Rezvan from Keybanc and Josh Silverstein from UBS lowered their price targets, while Neal Dingmann from Truist Securities maintained his, and Mark Lear from Piper Sandler raised his. Murphy Oil's financials show a revenue decline of -18.23% for the last quarter, a high net margin of 26.77%, but a lower than average ROE of 4.83% and a strong ROA of 2.53%. The company's debt-to-equity ratio is healthy at 0.45.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

SM

Analysts have updated their ratings and price targets for SM Energy (NYSE:SM), with a mix of bullish and neutral stances. Over the past three months, ratings have varied, with the current consensus being 1 bullish, 2 somewhat bullish, and 1 indifferent. The average 12-month price target is now $45.00, down from $47.75, with a high estimate of $51.00 and a low of $40.00. Key analysts from Keybanc, Raymond James, Mizuho, and Susquehanna have adjusted their price targets, with three lowering and one raising their target. SM Energy's financials show a -22.7% revenue decline over 3 months, but strong profitability with a net margin of 34.76% and above-average ROE and ROA. The company has a lower-than-average debt-to-equity ratio of 0.46.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) has received mixed analyst ratings over the past three months, with 12 analysts offering a range of bullish to bearish perspectives. The average 12-month price target is $58.5, with a high of $77.00 and a low of $37.00. However, there has been a 17.89% decrease in the average price target, indicating a negative shift in sentiment. Analysts from firms like JMP Securities, Raymond James, HC Wainwright & Co., Cantor Fitzgerald, JP Morgan, Morgan Stanley, and Evercore ISI Group have provided various ratings and price target adjustments. Mirum Pharmaceuticals is a biopharmaceutical company with a focus on rare and orphan diseases, and its product Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The company has shown a revenue growth rate of 154.13% as of September 30, 2023, but faces challenges with a net margin of -49.42% and a debt-to-equity ratio of 1.14.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

LPX

Louisiana-Pacific (NYSE:LPX) has been the subject of varying opinions from 6 analysts over the past three months, with recent ratings ranging from bullish to indifferent. The average 12-month price target for LPX has risen to $74.67, up 4.29% from the previous target of $71.60. Analysts from firms including TD Cowen, Truist Securities, RBC Capital, and Goldman Sachs have updated their price targets and ratings, reflecting their latest views on the company's performance. Louisiana-Pacific, a producer of oriented strand board and engineered wood siding, has a market cap above industry average, a negative revenue trend of -14.55% over 3 months, a high net margin of 16.21%, an ROE of 8.09%, an ROA of 5.04%, and a low debt-to-equity ratio of 0.25.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm